From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|July 25, 2022
Daily Medication Pearl: Piperacillin and Tazobactam (Zosyn)
Author(s)Saro Arakelians, PharmD
Piperacillin and tazobactam (Zosyn) is indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.
Advertisement
Medication Pearl of the Day: Piperacillin and Tazobactam (Zosyn)
Indication: Piperacillin and tazobactam (Zosyn) is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.
Insight:
- Dosing: The usual daily dose of Zosyn for adults is 3.375 g every 6 hours, totaling 13.5 g.
- Dosage forms: Zosyn for injection 2.25 g, 3.375 g, and 4.5 g lyophilized powder for reconstitution in single-dose vials and 40.5 g lyophilized powder for reconstitution in pharmacy bulk vials.
- Adverse events: The most common adverse reactions (incidence >5%) are diarrhea, constipation, nausea, headache, and insomnia.
- Mechanism of action: Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. In vitro, piperacillin is active against a variety of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins.
Source:
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5